Details
Stereochemistry | ACHIRAL |
Molecular Formula | Mg.O |
Molecular Weight | 40.3044 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O--].[Mg++]
InChI
InChIKey=AXZKOIWUVFPNLO-UHFFFAOYSA-N
InChI=1S/Mg.O/q+2;-2
DescriptionSources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium
phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.
CNS Activity
Sources: DOI: 10.1002/0471238961.0218151310010311.a02Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQChttps://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
[Magnesium--an alternative in treatment resistant tachyarrhythmias]. | 1977 May 30 |
|
Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms. | 1979 Nov |
|
Characterization of the prolactin receptor in human prostate. | 1983 Nov |
|
Regulation of membrane histamine H1-receptor binding sites by guanine nucleotides, mono- and divalent cations. | 1986 Apr |
|
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes. | 1986 Sep |
|
Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. | 1987 Mar 30 |
|
Effect of magnesium diet in gentamicin-induced acute renal failure in rats. | 1989 |
|
Polylysine specifically activates the insulin-dependent insulin receptor protein kinase. | 1989 Jun 15 |
|
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium]. | 1989 Sep |
|
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain. | 1990 Feb 5 |
|
Magnesium inhibits the hypertensive but not the cardiotonic actions of low-dose epinephrine. | 1991 Jun |
|
Persistent paralysis in critically ill patients after long-term administration of vecuronium. | 1992 Aug 20 |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Cocaine-induced cerebrovasospasm and its possible mechanism of action. | 1994 Mar |
|
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid. | 1995 Mar |
|
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. | 1996 Jun |
|
Tissue and blood levels of zinc, copper, and magnesium in nitric oxide synthase blockade-induced hypertension. | 2000 Nov |
|
Evidence supporting a role for KCl cotransporter in the thick ascending limb of Henle's loop. | 2001 Nov |
|
Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. | 2002 Jul |
|
Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants. | 2002 Nov |
|
A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients. | 2003 |
|
Cell-associated magnesium and QT dispersion in hemodialysis patients. | 2003 Jan |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Elevated levels of ferrimagnetic metals in foodchains supporting the Guam cluster of neurodegeneration: do metal nucleated crystal contaminants [corrected] evoke magnetic fields that initiate the progressive pathogenesis of neurodegeneration? | 2004 |
|
The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. | 2004 Aug |
|
Ablation of calcitonin/calcitonin gene-related peptide-alpha impairs fetal magnesium but not calcium homeostasis. | 2004 Aug |
|
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. | 2004 Aug 18 |
|
Magnesium influence on morphine--induced pharmacodependence in rats. | 2004 Mar |
|
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. | 2004 May |
|
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain. | 2006 Apr 25 |
|
Structure of pyrimidine 5'-nucleotidase type 1. Insight into mechanism of action and inhibition during lead poisoning. | 2006 Jul 21 |
|
Activation and enzymatic characterization of recombinant human kallikrein 8. | 2006 Jun |
|
The expression of genes for transepithelial calcium-transporting proteins in the bovine duodenum. | 2006 Mar |
|
Kinetic properties of chimeric class I aldehyde dehydrogenases for retinal isomers. | 2006 Oct |
|
The specific, submicromolar-Km ADP-ribose pyrophosphatase purified from human placenta is enzymically indistinguishable from recombinant NUDT9 protein, including a selectivity for Mn2+ as activating cation and increase in Km for ADP-ribose, both elicited by H2O2. | 2006 Oct |
|
Divalent-metal-dependent nucleolytic activity of Cu, Zn superoxide dismutase. | 2006 Oct |
|
Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. | 2007 Nov |
|
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007 Sep |
|
The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. | 2007 Sep |
|
[The characterization of central neuromediation in rats fed with magnesium-deprived diet before and after magnesium replenishment]. | 2008 Jul |
|
Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. | 2009 Dec |
|
Magnesium modifies fentanyl-induced local antinociception and hyperalgesia. | 2009 Nov |
|
Evidence that TRPM7 is required for breast cancer cell proliferation. | 2009 Sep |
|
Hair tissue mineral analysis and metabolic syndrome. | 2009 Sep |
|
Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). | 2010 Apr 13 |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. | 2011 Feb |
|
Millimolar Mn2+ influences agonist binding to 5-HT1A receptors by inhibiting guanosine nucleotide binding to receptor-coupled G-proteins. | 2011 Jan |
|
Mechanically enforced bond dissociation reports synergistic influence of Mn2+ and Mg2+ on the interaction between integrin α7β1 and invasin. | 2011 Jul-Aug |
|
Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis. | 2013 |
|
Ofloxacin induces apoptosis via β1 integrin-EGFR-Rac1-Nox2 pathway in microencapsulated chondrocytes. | 2013 Feb 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27995243
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm
were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA02AA02
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
JECFA EVALUATION |
INS-530
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
WHO-ATC |
A12CC10
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
NCI_THESAURUS |
C29697
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-530
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
WHO-VATC |
QA06AD02
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
WHO-ATC |
A02AA02
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
WHO-ATC |
A06AD02
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
CFR |
21 CFR 184.1431
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
WHO-VATC |
QA12CC10
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
||
|
CFR |
21 CFR 178.3297
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12130MIG
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
1309-48-4
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
3A3U0GI71G
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
D008277
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
215-171-9
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
C29242
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
6582
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
4293
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
1652
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200572
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
SUB14436MIG
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
SUB12129MIG
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
DTXSID9049665
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
3A3U0GI71G
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
Magnesium Oxide
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
100000087594
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
MAGNESIUM OXIDE
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | Description: A white powder; odourless. Light Magnesium oxide is very bulky, whereas heavy Magnesium oxide is a dense powder. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Antacid. Storage: Magnesium oxide should be kept in a tightly closed container.Labelling: The designation on the container should state whether it is light Magnesium oxide or heavy Magnesium oxide.Definition: Magnesium oxide contains not less than 98.0% and not more than 100.5% of MgO, calculated with reference to the ignited substance. | ||
|
MAGNESIUM OXIDE
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
1374281
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
31794
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
DB01377
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
6850729
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | |||
|
m7011
Created by
admin on Fri Dec 15 15:38:45 GMT 2023 , Edited by admin on Fri Dec 15 15:38:45 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD